KRAS G12C mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-KRAS-G12C |
|---|---|
| Type | Biomarker |
| Aliases | KRAS G12C мутація |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"functional_impact": "GTP-bound active KRAS; cysteine residue is the covalent target of sotorasib/adagrasib", "gene": "KRAS", "hotspots": ["G12C (codon 12, glycine→cysteine)"], "type": "activating missense"} |
| Measurement | MethodTumor-tissue NGS OR ctDNA NGS OR allele-specific PCR Sensitivity requirementStandard NGS |
| Actionability lookup | {"gene": "KRAS", "variant": "G12C"} |
| Related biomarkers | None declared |
Notes
Co-mutations with TP53, STK11, KEAP1 may modulate response. STK11 + KRAS G12C predicts poorer ICI response.
Used By
Actionability
BMA-KRAS-G12C-CRC- KRAS G12C in mCRC (~3-4%): single-agent KRASG12C inhibitors insufficient (intrinsic EGFR...BMA-KRAS-G12C-ENDOMETRIAL- KRAS mutations occur in ~15-25% of endometrioid endometrial cancers; G12C is a minority s...BMA-KRAS-G12C-GASTRIC- KRAS G12C in gastric/GEJ adenocarcinoma is rare. Sotorasib basket data limited; trial-onl...BMA-KRAS-G12C-HCC- KRAS G12C in HCC is rare. Sotorasib not approved in HCC; trial-only.BMA-KRAS-G12C-MM- KRAS G12C in myeloma — rare; tissue-agnostic G12Ci (sotorasib/adagrasib) not approved in...BMA-KRAS-G12C-NSCLC- KRAS G12C in advanced NSCLC (~13% of adenocarcinoma): sotorasib (CodeBreaK 100/200) and a...BMA-KRAS-G12C-OVARIAN- KRAS G12C in ovarian (mostly low-grade serous) is rare. Tissue- agnostic basket data (Cod...BMA-KRAS-G12C-PDAC- KRAS G12C is rare in PDAC (~1-2%, vs ~30% G12D and ~25% G12V). Sotorasib (CodeBreaK 100 P...
Biomarker
BIO-GNAS- GNAS activating mutation (Gα_s protein)BIO-HRAS- HRAS mutationBIO-KRAS-G12D- KRAS G12D mutationBIO-KRAS-G12V- KRAS G12V mutationBIO-PTPN11- PTPN11 activating mutation (SHP2)
Indications
IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMAB- IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMABIND-NSCLC-2L-KRAS-G12C-ADAGRASIB- IND-NSCLC-2L-KRAS-G12C-ADAGRASIBIND-NSCLC-2L-KRAS-G12C-SOTORASIB- IND-NSCLC-2L-KRAS-G12C-SOTORASIBIND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL- IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXELIND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMO- IND-NSCLC-DRIVER-NEG-MET-1L-NIVO-IPI-CHEMOIND-NSCLC-KRAS-G12C-MET-2L- IND-NSCLC-KRAS-G12C-MET-2L
Questionnaires
QUEST-CRC-1L-STUB- Colorectal carcinoma — first lineQUEST-NSCLC-1L-STUB- Non-small cell lung cancer — first line
Red flag
RF-NSCLC-HIGH-RISK-BIOLOGY- Actionable molecular driver detected (EGFR / ALK / ROS1 / KRAS G12C / BRAF V600E / MET ex...
Tests
TEST-NSCLC-NGS-PANEL- NSCLC comprehensive NGS panel (DNA + RNA fusion)